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Acute Lymphoblastic Leukaemia
Acute Lymphoblastic Leukaemia (ALL) is a disease of
lymphoid progenitor cells. It can affect both adults and
kids, being the most common kind of cancer in children. It
has an 80% cure ratio. Treatment failure is mostly related
to relapses.1 Children with ALL can be classified in risk
groups (High and Low). If the subject has not any of the
characteristics mentioned in Table 1, they will be
classified as low risk.2
BACKGROUND
HYPOTHESIS & OBJECTVES
MATERIAL AND METHODS
Population
Subjects from one to ten years old, diagnosed with ALL and characterized as
low risk, following the parameters from Table 1. A skin biopsy will be taken
from every patient.
Follow-up
A follow-up will be made during their treatment, and for 5 years after ending
it.
It will be described whether the subjects undergo any CNS metastasis or not.
Genotyping
EXPECTED RESULTS
It is expected to find a statistical
significant relationship between the
presence of TYMS overexpression
and a higher probability of CNS
relapses in patients with ALL treated
with the low risk protocol.
DIFFUSION PLAN
- Publication of the report in Blood Journal.
- Show the results in the 57th American Society of 
Hematology Annual Meeting & Exposition in 
Orlando, Florida.
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High risk group 
characteristics
Age <1 or >10 years 
Leukocyte count 
>50·109/L
Central Nervous System 
(CNS) involvement 
Testicular involvement
BCR-ABL t(9;22)
MLL-AF4 t(4;11)
E2A-PBX1 t(1;19)
Normal to medium TS 
expression
TYMS 2/2
TYMS 2/3(C or G)
TYMS 3C/3C
TYMS 3C/3G
High TS expression TYMS 3G/3G
TYMS
TYMS gene encodes the protein
Thymidylate Synthase (TS), an important
enzyme for DNA replication and repair.
The expression level of TYMS is a marker
used to predict the outcome of the
treatment of several cancers, as TS is a
chemotherapy target.3
There are different TYMS alleles. The differences between them are located in the 5’
Untranslated Region (UTR), where there is a tandem repeat of 28bp, including a
Upstream Stimulating Factor (USF) family of E-boxes. Its number of repetitions affects
the transcription and translation efficiency of the mRNA produced. There are two
different alleles: double-repeat and triple-repeat (which increases the expression of
TS). There is another polymorphism placed in the additional E-box of the triple-repeat
allele. This one is a single nucleotide polymorphism (SNP) GC, resulting in a double-
repeat like TS expression.
Table 1: High risk 
group characteristics2
Hypothesis: TYMS overexpression decreases the effectiveness of the methotrexate
treatment in childhood ALL, leading to a higher probability of CNS relapses on low risk
patients.
Objectives:
• Characterizing a group of low risk patients with childhood ALL for the gene TYMS,
and following up on their progression.
• Analysing the results of the follow-up, taking into consideration which
polymorphisms every patient has.
• Proving if the genotype TYMS 3G/3G leads to a higher probability of CNS relapse in
lower-risk group patients.
• Publishing the results to improve the treatment and follow-up of the children
affected by ALL in hospitals.
Figure 2: Structure of TYMS alleles. Adapted from previous 
report.4
Table 2:  
Relationship 
between TYMS 
genotype and 
its phenotype.
Figure 1: Methylation of dUMP to dTMP 
by TS, inhibited by drugs such as Fluoro-
uracil (5-FU) and Methotrexate (MTX)
Statistical analysis 
Fisher’s exact test performed in the R statistical computing environment will be done,
testing the number of relapses versus the polymorphism that every subject has.
Figure 3: Expected number of CNS 
relapses regarding TS expression
